MedCity News December 1, 2022
Thanks to the convergence of cloud technologies, AI, and refined lung data, we are in a new era for those with chronic lung disease. In this new world, lung intelligence provides fast, precision measures of treatment efficacy so new drugs can blaze through the trial pipeline.
More than 500 million people on the planet have chronic lung disease — all eager for better therapies. Unfortunately, the wait for novel treatment is a long and expensive one — it takes 14 years and more than $1 billion, with a failure rate of 95%, to get a single drug from research labs to pharmacies.
Many of the issues that contribute to these high-cost failures and delays in clinical trials have something in...
Today's Sponsors
Today's Sponsor